Figure 3. Probability of symptom (cAMS>=17) on the basis of levels of bioavailable testosterone (cFT) and testosterone secreting index (TSI). Symptom was defined by cAMS score (>=17), which contained 10 items related with cFT. Obvious increases of the trend of probability of symptom were observed with decreased cFT, and TSI. Thresholds for the significant changes of the probability of symptom with hormones were denoted by vertical lines.